ImmunoGen Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of ImmunoGen Inc in the market include pharmaceutical companies such as Roche Holding AG, Pfizer Inc, and Bristol-Myers Squibb Company.

ImmunoGen Inc is a pharmaceutical company founded in 1981 and headquartered in Waltham, Massachusetts. With a focus on developing targeted antibody-drug conjugates (ADCs), ImmunoGen has been a pioneer in the field of cancer therapeutics. The company's innovative technology aims to deliver treatment directly to cancer cells while minimizing damage to healthy cells. ImmunoGen has partnered with various pharmaceutical companies to accelerate the development and commercialization of ADCs. Over the years, ImmunoGen has gained recognition for its expertise in ADC research and continues to advance its pipeline of novel therapies, making significant contributions to the field of oncology.

ImmunoGen Inc has achieved several significant milestones. The company successfully developed and obtained FDA approval for its targeted anti-cancer therapy, Kadcyla. This milestone revolutionized the treatment of HER2-positive breast cancer, providing a more effective and less toxic treatment option. ImmunoGen Inc also partnered with leading pharmaceutical companies like Roche, Amgen, and Takeda, further validating their novel technology platform. Additionally, the company has made notable progress in advancing their pipeline candidates, including IMGN632 and IMGN151, targeting various hematological malignancies. These achievements demonstrate ImmunoGen Inc's commitment to groundbreaking research and the potential to significantly impact cancer treatment.

ImmunoGen Inc, a leading biotechnology company, primarily operates in the United States. With its headquarters located in Waltham, Massachusetts, ImmunoGen Inc primarily focuses on the development and commercialization of innovative antibody-drug conjugate (ADC) therapies for the treatment of various types of cancer. By leveraging its proprietary technology platform, ImmunoGen Inc has gained recognition and presence in the US healthcare industry. As a US-based company, ImmunoGen Inc has been actively involved in collaborations and partnerships with other biopharmaceutical companies to expand its global reach and potentially introduce its revolutionary ADC therapies to patients worldwide.

ImmunoGen Inc represents values of innovation, dedication, and patient-centricity. With a strong corporate philosophy focused on developing targeted cancer therapies, ImmunoGen is committed to improving the lives of patients battling cancer. By harnessing the power of its unique Antibody-Drug Conjugate (ADC) technology, ImmunoGen strives to deliver transformative treatments that specifically target cancer cells while sparing healthy cells. The company's dedication to research, collaboration, and delivering breakthrough therapies sets it apart in the biotechnology industry. ImmunoGen Inc prioritizes patient well-being and relentlessly pursues advancements in precision medicine to shape the future of cancer treatment.

19 analysts currently rate the ImmunoGen stock: 7 recommend buying, 12 holding and 0 selling. For 2026, analysts expect ImmunoGen to generate revenue of 757,20 M USD and earnings per share of 0,75 USD.

ImmunoGen Analyytikkojen kursstavoitteet 2026

The ImmunoGen share (IMGN) is listed on 8 stock exchanges, including: NASDAQ (IMGN), XETRA (IMU.DE), Frankfurt (IMU.F), München (IMU.MU), Düsseldorf (IMU.DU), London (0A8K.L), London (0A8K.L), SIX (Zürich) (IMU.SW).

ImmunoGen Inc is a biotechnology company specializing in the development of innovative therapy approaches for the treatment of cancer. The company's business model is based on the discovery and development of drugs that selectively destroy cancer cells while sparing the surrounding healthy tissue. ImmunoGen utilizes its own technology platform called Antibody-Drug Conjugates (ADCs) for this purpose. ADCs are a new class of drugs that can target cancer cells specifically. They consist of three components: an antibody that binds specifically to cancer cells, a drug that kills the cancer cells, and a linker that connects the two components. By combining these components, ADCs enable targeted tumor destruction and reduce the burden on healthy tissue. ImmunoGen's flagship product is the ADC candidate Mirvetuximab Soravtansine, which is currently being tested in Phase 3 clinical trials for the treatment of ovarian cancer. Mirvetuximab Soravtansine has higher efficacy and fewer side effects compared to conventional chemotherapeutics. In addition, ImmunoGen is developing other ADC candidates in various stages of clinical development. In addition to ADC development, ImmunoGen also operates a service business focused on the manufacturing and optimization of ADCs for other pharmaceutical companies. ImmunoGen has extensive experience in ADC manufacturing and offers this expertise as a service. Furthermore, ImmunoGen collaborates with other companies and research institutions to further develop and expand the ADC technology platform. Another business area of ImmunoGen is the research and development of new technology platforms. The company continuously invests in the exploration of new approaches for cancer therapy. This includes the ABC technology platform, which aims to improve the short-term stability of ADCs while increasing their efficacy. ImmunoGen aims to become a leading biotechnology company in the field of cancer therapy. With its innovative ADC technology platform and the development of promising candidates like Mirvetuximab Soravtansine, ImmunoGen is on track to achieve this goal. With a broad portfolio of products and services, ImmunoGen is well-equipped to withstand an increasingly complex and volatile industry.

odotettu liikevaihto ImmunoGen on 757,20 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto ImmunoGen on 216,89 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

P/E-suhdetta ei voida laskea ImmunoGen:lle tällä hetkellä.

P/S-suhdetta ei voida laskea ImmunoGen:lle tällä hetkellä.

ImmunoGen:n Eulpool-laatuscore on 4/10.

ImmunoGen:n ISIN on US45253H1014. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

ImmunoGen:n WKN on 878613. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

ImmunoGen:n ticker on IMGN. Tämä pörssinoteeraus käytetään ImmunoGen-osakkeiden kauppaan pörssissä.

ImmunoGen kuuluu sektoriin 'Terveydenhuolto'.

ImmunoGen:n osingot jaetaan valuutassa USD.